642 related articles for article (PubMed ID: 33687890)
1. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
3. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
4. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
7. [Application of PROTACs in Hematological Malignancies--Review].
Jia YN; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
[TBL] [Abstract][Full Text] [Related]
8. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
9. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degradation: elements of PROTAC design.
Paiva SL; Crews CM
Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
[TBL] [Abstract][Full Text] [Related]
11. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
12. The Present and Future of Novel Protein Degradation Technology.
Xia L; Liu W; Song Y; Zhu H; Duan Y
Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
[TBL] [Abstract][Full Text] [Related]
13. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
14. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
16. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
17. A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications.
Stacey P; Lithgow H; Lewell X; Konopacka A; Besley S; Green G; Whatling R; Law R; Röth S; Sapkota GP; Smith IED; Burley GA; Harling J; Benowitz AB; Queisser MA; Muelbaier M
SLAS Discov; 2021 Aug; 26(7):885-895. PubMed ID: 34041938
[TBL] [Abstract][Full Text] [Related]
18. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
[TBL] [Abstract][Full Text] [Related]
19. PROTACs: New method to degrade transcription regulating proteins.
Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
[TBL] [Abstract][Full Text] [Related]
20. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]